Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Want to see SCNI full AI Analyst Report?
Top Page
Scinai Immunotherapeutics
(NASDAQ:SCNI)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.36
▼(-54.49% Downside)
Action:Reiterated
Date:06/10/26
The score is held down primarily by weak financial performance (continued losses and significant cash burn despite improved leverage) and bearish technicals (trading well below key moving averages with negative MACD). Valuation is only mildly supportive because the negative P/E is not meaningful and there is no dividend yield.
Positive Factors
CDMO Capability Expansion
Acquiring Recipharm Israel creates a second manufacturing site and consolidates CDMO activities, structurally shifting the company toward fee-for-service revenue. Over months this should diversify income, provide operational scale for biologics and injectables, and reduce reliance on R&D-only funding cycles.
Negative Factors
Persistent Cash Burn
Sustained negative operating cash flow and free cash flow indicate the business continues to consume cash to fund operations. Over a multi-month horizon this necessitates repeated financing, constrains investment choices, and increases execution risk if capital markets tighten or grant timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO Capability Expansion
Acquiring Recipharm Israel creates a second manufacturing site and consolidates CDMO activities, structurally shifting the company toward fee-for-service revenue. Over months this should diversify income, provide operational scale for biologics and injectables, and reduce reliance on R&D-only funding cycles.
Read all positive factors
Scinai Immunotherapeutics (SCNI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.14M
Dividend YieldN/A
Average Volume (3M)101.31K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-1.81%
EPS Growth-217.37%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3838.80
Shares Outstanding3,959,792
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit-0.47
Enterprise Value/Ebitda-0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scinai Immunotherapeutics Business Overview & Revenue Model
Company Description
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a rang...
How the Company Makes Money
null...
Scinai Immunotherapeutics Earnings Call Summary
Earnings Call Date:Aug 15, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive and negative aspects. While there were notable achievements such as the reduction in net loss, positive regulatory feedback, and growth in the CDMO business, there were also challenges like a significant decrease in cash position and negative shareholder equity. The sentiment is balanced with both opportunities and financial restructuring challenges.Positive Updates
Reduction in Operating Expenses
R&D expenses decreased to $2.79 million compared to $3.45 million the previous year, and marketing and G&A expenses were reduced to $1 million from $2.3 million the previous year.
Negative Updates
Cash Position Decrease
Cash available as of June 30, 2024, was $3.21 million, down from $7.63 million at the end of June 30, 2023.
Read all updates
Q2-2024 Updates
Positive
Negative
Reduction in Operating Expenses
R&D expenses decreased to $2.79 million compared to $3.45 million the previous year, and marketing and G&A expenses were reduced to $1 million from $2.3 million the previous year.
Read all positive updates
Company Guidance
In the Q2 2024 earnings call for Scinai Immunotherapeutics, CEO Amir Reichman provided detailed guidance on the company's strategic objectives and financial outlook. Scinai aims to fast-track IL-17 development to toxicology studies and increase CDMO business unit sales to $1.25 million. The company plans to reduce R&D risks by partnering with other pharma companies while maintaining careful spending to control its burn rate. Financially, Scinai reported a net loss of $4.48 million for the first half of 2024, a decrease from $7.28 million in the same period in 2023, attributed to reduced operating expenses. In addition, Scinai is working on a debt-to-equity restructuring deal expected to positively impact shareholder equity by approximately $19 million. The company also announced a $2 million equity commitment from Daniel Stone, which will provide additional financial flexibility. Overall, the guidance highlights Scinai's focus on advancing its R&D pipeline and CDMO business while ensuring financial stability and growth.Scinai Immunotherapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.31M | 658.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.65M | -580.00K | -512.67K | -559.80K | -747.65K |
| EBITDA | -6.53M | -6.99M | -9.19M | -10.50M | -10.39M |
| Net Income | -8.31M | 4.80M | -6.50M | -5.80M | -8.21M |
Balance Sheet | |||||
| Total Assets | 11.63M | 13.45M | 17.47M | 27.07M | 32.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.66M | 1.96M | 4.87M | 14.07M | 17.37M |
| Total Debt | 2.27M | 2.09M | 20.56M | 21.54M | 29.23M |
| Total Liabilities | 3.52M | 3.47M | 22.04M | 28.83M | 31.05M |
| Stockholders Equity | 8.10M | 9.98M | -4.57M | -1.76M | 982.00K |
Cash Flow | |||||
| Free Cash Flow | -6.05M | -6.35M | -10.02M | -8.10M | -7.57M |
| Operating Cash Flow | -6.03M | -6.33M | -9.38M | -7.26M | -7.43M |
| Investing Cash Flow | -24.00K | -12.00K | -637.00K | -836.00K | -139.00K |
| Financing Cash Flow | 5.77M | 3.44M | 1.09M | 6.78M | 21.43M |
Scinai Immunotherapeutics Technical Analysis
Negative
0.78
Price Trends
0.51
Negative
0.64
Negative
0.90
Negative
Market Momentum
-0.06
Positive
32.70
Neutral
25.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.51, and below the 200-day MA of 0.90, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of 25.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNI.
Scinai Immunotherapeutics Risk Analysis
Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scinai Immunotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
SCNI
Scinai Immunotherapeutics
0.32
-1.89
-85.50%
GTBP
GT Biopharma
0.51
-2.54
-83.15%
ADTX
Aditxt
0.01
-32,462.63
-100.00%
CERO
CERo Therapeutics Holdings
0.01
-10.67
-99.91%
PBM
Psyence Biomedical
3.15
-26.60
-89.41%
CDT
CDT Equity
1.02
-458.98
-99.78%
Scinai Immunotherapeutics Corporate Events
Scinai Immunotherapeutics Boosts CDMO Platform With Recipharm Israel Deal and Q1 2026 Turn to Profit
Jun 15, 2026
On June 10, 2026, Scinai Immunotherapeutics reported first-quarter 2026 results and detailed a strategic expansion of its CDMO platform through the completed acquisition of Recipharm Israel, adding a second manufacturing site in Yavne and consolid...
Scinai Immunotherapeutics Clarifies Chairman Service Agreement Ahead of June 16 AGM
Jun 8, 2026
On May 12, 2026, Scinai Immunotherapeutics notified shareholders and regulators that its Annual General Meeting of Shareholders is scheduled for June 16, 2026, and included a proxy proposal to extend the services agreement of board chairman Mark G...
Scinai Immunotherapeutics Sets June 16, 2026 Shareholder Meeting to Expand Share Capital and Approve Executive Incentives
May 12, 2026
On May 12, 2026, Scinai Immunotherapeutics filed a report announcing its Annual General Meeting of Shareholders, scheduled for June 16, 2026, in Tel Aviv, with ADS holders of record as of May 13, 2026 eligible to vote. The agenda includes re-elect...
Scinai Immunotherapeutics Files Pro Forma Financials After February Acquisition of Recipharm Israel
May 8, 2026
On February 17, 2026, Scinai Immunotherapeutics completed the acquisition of Recipharm Israel Ltd., which has since been renamed Scinai Biopharma Services Ltd., marking a strategic step in building out its CDMO-focused subsidiary operations. On Ma...
Scinai Immunotherapeutics Raises $2.61 Million in ADS and Warrant Financing to Expand CDMO and Immunotherapy Programs
Apr 27, 2026
On April 23, 2026, Scinai Immunotherapeutics Ltd. entered into a securities purchase agreement with institutional and accredited investors for a private placement of 5,208,333 American Depositary Shares at $0.48 per ADS, together with Series A and...
Scinai Immunotherapeutics Revises €12M FENG Bid and Extends PinCell Option Timeline
Mar 23, 2026
On March 2, 2026, Scinai Immunotherapeutics announced it had signed a second amendment to its binding option agreement to acquire Italian biotech PinCell S.r.l. and submitted a revised application under the European Funds for the Modern Economy SM...
Scinai Immunotherapeutics Faces Nasdaq Minimum Bid Price Deficiency, Given Until September to Regain Compliance
Mar 19, 2026
On March 16, 2026, Scinai Immunotherapeutics disclosed that it had received a Nasdaq notice on March 12, 2026 stating its American Depositary Shares had traded below the $1.00 minimum bid price for 30 consecutive business days, putting it out of c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.